Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Alex B. Blair

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3297-2299; OpenAlex author ID A5070188771. Sources: OpenAlex.

Their work

Papers
41 (first author 8, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
133
Papers, trials and grants by year

2017: 2 papers · 2018: 7 papers · 2019: 9 papers · 2020: 2 papers · 2021: 7 papers · 2022: 5 papers · 2023: none · 2024: 1 paper · 2025: 5 papers · 2026: 3 papers

Papers 41

  1. CXCR2 blockade overcomes the NETosis-mediated resistance to MEK inhibition in pancreatic cancer models. First author DOI 10.1172/jci196622↗
  2. The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20366-0↗
  3. ASO Visual Abstract: The Landmark Series-Mutation-Based Therapy of Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20458-x↗
  4. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
  5. ASO Author Reflections: Targeted Treatment for a Rare Subset of Pancreatic Cancer? Co-author DOI 10.1245/s10434-024-16451-x↗
  6. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  7. ASO Author Reflections: Shifting Paradigms in the Management of Locally Advanced Pancreatic Cancer with Ablative Radiation. Co-author DOI 10.1245/s10434-025-17343-4↗
  8. Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17244030↗
  9. Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration. Co-author DOI 10.1186/s13045-024-01576-z↗
  10. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  11. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. First author DOI 10.1016/j.sopen.2022.07.007↗
  12. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. Co-author DOI 10.1053/j.gastro.2022.06.027↗
  13. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. First author DOI 10.1245/s10434-021-10663-1↗
  14. The Role of Diffusion-Weighted Magnetic Resonance Imaging in Staging After Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma: Reply. Co-author DOI 10.1245/s10434-022-11737-4↗
  15. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  16. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2020.11.041↗
  17. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. First author DOI 10.1097/sla.0000000000003568↗
  18. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003570↗
  19. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  20. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. First author DOI 10.20892/j.issn.2095-3941.2020.0273↗
  21. CT Radiomics-Based Preoperative Survival Prediction in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.20.23490↗
  22. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004200↗
  23. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000351↗
  24. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Co-author DOI 10.1007/s11605-018-3966-8↗
  25. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. First author DOI 10.1016/j.ejso.2019.04.007↗
  26. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. First author DOI 10.1016/j.hpb.2018.12.002↗
  27. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001376↗
  28. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002734↗
  29. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Co-author DOI 10.1097/sla.0000000000002753↗
  30. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-18-4192↗
  31. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. Co-author DOI 10.1172/jci124077↗
  32. Lessons learned by features of pancreatic ductal adenocarcinoma and its tumor microenvironment. Co-author DOI 10.21037/atm.2019.01.32↗
  33. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25288↗
  34. Pancreaticoduodenectomy and Superior Mesenteric Vein Resection Without Reconstruction for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-018-3684-2↗
  35. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2017.12.021↗
  36. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conven… Co-author DOI 10.1016/j.surg.2017.11.027↗
  37. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? First author DOI 10.1097/sla.0000000000002672↗
  38. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. Co-author DOI 10.1186/s40425-018-0435-6↗
  39. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6558-7↗
  40. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  41. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/cco.2017.06.04↗

Closest collaborators

The 25 strongest of 133 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 24 shared papers, 2017–2022 · strength 2.37
  2. Lei Zheng · 19 shared papers, 2017–2024 · strength 1.90
  3. Christopher Lee Wolfgang · 18 shared papers, 2017–2022 · strength 1.60
  4. Matthew John Weiss · 18 shared papers, 2017–2022 · strength 1.57
  5. Georgios Gemenetzis · 14 shared papers, 2018–2022 · strength 1.42
  6. Richard Andrew Burkhart · 15 shared papers, 2018–2022 · strength 1.40
  7. Vincent P. Groot · 14 shared papers, 2018–2022 · strength 1.36
  8. Kevin C. Soares · 5 shared papers, 2017–2025 · strength 1.09
  9. McKenzie L. Schaefer · 2 shared papers, 2026 · strength 1.00
  10. Susan Tsai · 2 shared papers, 2026 · strength 1.00
  11. Alice Chia-Chi Wei · 3 shared papers, 2025 · strength 0.96
  12. Ding Ding · 11 shared papers, 2018–2022 · strength 0.96
  13. Elizabeth M. Jaffee · 7 shared papers, 2018–2026 · strength 0.90
  14. Daniel A. Laheru · 9 shared papers, 2017–2022 · strength 0.77
  15. Brian T. Herbst · 4 shared papers, 2020–2026 · strength 0.74
  16. Ammar A. Javed · 8 shared papers, 2018–2022 · strength 0.70
  17. Elliot K. Fishman · 8 shared papers, 2017–2022 · strength 0.67
  18. Ralph H. Hruban · 8 shared papers, 2017–2022 · strength 0.65
  19. Noah S Rozich · 5 shared papers, 2019–2024 · strength 0.61
  20. Jun Yu · 7 shared papers, 2018–2021 · strength 0.59
  21. Keyu Li · 5 shared papers, 2020–2024 · strength 0.57
  22. Arsen Osipov · 5 shared papers, 2021–2024 · strength 0.57
  23. Stephen T. Muth · 5 shared papers, 2018–2021 · strength 0.52
  24. Amol Kumar Narang · 6 shared papers, 2017–2022 · strength 0.51
  25. Joseph M. Herman · 6 shared papers, 2017–2022 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.